3-硼-2-甲氧基苯甲酸 | 913836-10-9

• 物质功能分类: 医药中间体 - 原料药中间体
• 分子结构分类: 有机化合物 - 苯类化合物 - 苯和取代衍生物
• 中文名称: 3-硼-2-甲氧基苯甲酸
• 中文别名: 3-羧基-2-甲氧基苯硼酸
• 英文名称: 3-carboxy-2-methoxy-phenylboronic acid
• 英文别名: 3-borono-2-methoxybenzoic acid
• CAS: 913836-10-9
• 化学式: C₈H₉BO₅
• mdl: MFCD09027237
• 分子量: 195.967
• InChiKey: QUWLFFYGKXZCER-UHFFFAOYSA-N

物化性质

• 熔点：
  152-155℃
• 沸点：
  456.0±55.0 °C(Predicted)
• 密度：
  1.39±0.1 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  0.9
• 重原子数：
  14
• 可旋转键数：
  3
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.125
• 拓扑面积：
  87
• 氢给体数：
  3
• 氢受体数：
  5

安全信息

• 危险品标志：
  Xi
• 危险性防范说明：
  P261,P264,P272,P280,P302+P352,P305+P351+P338,P333+P313,P337+P313,P363,P501
• 危险性描述：
  H317,H319

SDS

Material Safety Data Sheet

---

Section 1. Identification of the substance
3-Borono-2-methoxybenzoic acid
Product Name:
Synonyms: 3-Carboxy-2-methoxyphenylboronic acid

---

Section 2. Hazards identification
Harmful by inhalation, in contact with skin, and if swallowed.
H315: Causes skin irritation
H319: Causes serious eye irritation
H335: May cause respiratory irritation
P261: Avoid breathing dust/fume/gas/mist/vapours/spray
Wear protective gloves/protective clothing/eye protection/face protection
P280:
P305+P351+P338: IF IN EYES: Rinse cautiously with water for several minutes. Remove contact lenses if present
and easy to do – continue rinsing
P304+P340: IF INHALED: Remove victim to fresh air and keep at rest in a position comfortable for breathing
P405: Store locked up

---

Section 3. Composition/information on ingredients.
3-Borono-2-methoxybenzoic acid
Ingredient name:
CAS number: 913836-10-9

---

Section 4. First aid measures
Immediately wash skin with copious amounts of water for at least 15 minutes while removing
Skin contact:
contaminated clothing and shoes. If irritation persists, seek medical attention.
Eye contact: Immediately wash skin with copious amounts of water for at least 15 minutes. Assure adequate
flushing of the eyes by separating the eyelids with fingers. If irritation persists, seek medical
attention.
Inhalation: Remove to fresh air. In severe cases or if symptoms persist, seek medical attention.
Wash out mouth with copious amounts of water for at least 15 minutes. Seek medical attention.
Ingestion:

---

Section 5. Fire fighting measures
In the event of a fire involving this material, alone or in combination with other materials, use dry
powder or carbon dioxide extinguishers. Protective clothing and self-contained breathing apparatus
should be worn.

---

Section 6. Accidental release measures
Personal precautions: Wear suitable personal protective equipment which performs satisfactorily and meets local/state/national
standards.
Respiratory precaution: Wear approved mask/respirator
Hand precaution: Wear suitable gloves/gauntlets
Skin protection: Wear suitable protective clothing
Eye protection: Wear suitable eye protection
Methods for cleaning up: Mix with sand or similar inert absorbent material, sweep up and keep in a tightly closed container
for disposal. See section 12.
Environmental precautions: Do not allow material to enter drains or water courses.

---

Section 7. Handling and storage
Handling: This product should be handled only by, or under the close supervision of, those properly qualified
in the handling and use of potentially hazardous chemicals, who should take into account the fire,
health and chemical hazard data given on this sheet.
Storage: Store in closed vessels, refrigerated.

---

Section 8. Exposure Controls / Personal protection
Engineering Controls: Use only in a chemical fume hood.
Personal protective equipment: Wear laboratory clothing, chemical-resistant gloves and safety goggles.
General hydiene measures: Wash thoroughly after handling. Wash contaminated clothing before reuse.

---

Section 9. Physical and chemical properties
Not specified
Appearance:
Boiling point: No data
Melting point: No data
Flash point: No data
Density: No data
Molecular formula: C8H9BO5
Molecular weight: 196.0

---

Section 10. Stability and reactivity
Conditions to avoid: Heat, flames and sparks.
Materials to avoid: Oxidizing agents.
Possible hazardous combustion products: Carbon monoxide.

---

Section 11. Toxicological information
No data.

---

Section 12. Ecological information
No data.

---

Section 13. Disposal consideration
Arrange disposal as special waste, by licensed disposal company, in consultation with local waste
disposal authority, in accordance with national and regional regulations.

---

Section 14. Transportation information
Non-harzardous for air and ground transportation.

---

Section 15. Regulatory information
No chemicals in this material are subject to the reporting requirements of SARA Title III, Section
302, or have known CAS numbers that exceed the threshold reporting levels established by SARA
Title III, Section 313.

---

SECTION 16 - ADDITIONAL INFORMATION
N/A

反应信息

• 作为反应物：
  描述：

  3-硼-2-甲氧基苯甲酸 在 硫酸 正丁基锂 作用下， 以 四氢呋喃 、 1,4-二氧六环 、 正己烷 、 二氯甲烷 、 水 为溶剂， 反应 19.5h， 生成 2-methoxy-3-(2-((4-bromomethyl)-benzoylamino)-2-(2,9,9-trimethyl-3,5-dioxa-4-bora-tricyclo[6.1.1.0(2,6)]dec-4-yl)-ethyl)-benzoic acid tert-butyl ester
  参考文献：
  名称：

  [EN] BETA-LACTAMASE INHIBITORS
  [FR] INHIBITEURS DE BÉTA-LACTAMASES

  摘要：

  公开号：

  WO2010130708A9
• 作为产物：
  描述：

  2-甲氧基-3-甲基苯硼酸 在 potassium permanganate 、 sodium hydroxide 作用下， 以 水 为溶剂， 生成 3-硼-2-甲氧基苯甲酸
  参考文献：
  名称：

  [EN] PROCESS FOR BORON-CONTAINING COMPOUNDS
  [FR] PROCÉDÉ POUR COMPOSÉS CONTENANT DU BORE

  摘要：

  本文描述了含硼化合物、组成物以及其制备方法。

  公开号：

  WO2022076070A1

文献信息

• [EN] BETA-LACTAMASE INHIBITORS<br/>[FR] INHIBITEURS DE BÊTA-LACTAMASE
  申请人：VENATORX PHARMACEUTICALS INC

  公开号：WO2014089365A1

  公开（公告）日：2014-06-12

  Described herein are compounds and compositions that modulate the activity of beta-lactamases. In some embodiments, the compounds described herein inhibit beta-lactamase. In certain embodiments, the compounds described herein are useful in the treatment of bacterial infections.

  本文描述了调节β-内酰胺酶活性的化合物和组合物。在某些实施例中，所述化合物抑制β-内酰胺酶。在特定实施例中，所述化合物在治疗细菌感染方面是有用的。
• INHIBITING FATTY ACID SYNTHASE (FASN)
  申请人：Forma Therapeutics, Inc.

  公开号：EP3636637A1

  公开（公告）日：2020-04-15

  The present disclosure is directed to inhibitors of FASN. The compounds can be useful in the treatment of disease or disorders associated with the inhibition of FASN. For instance, the disclosure is concerned with compounds and compositions for inhibition of FASN, methods of treating, preventing, or ameliorating diseases or disorders associated with the inhibition of FASN, and methods of synthesis of these compounds.

  本公开涉及FASN的抑制剂。这些化合物可用于治疗与FASN抑制相关的疾病或疾病。例如，本公开涉及用于抑制FASN的化合物和组合物，治疗、预防或改善与FASN抑制相关的疾病或疾病的方法，以及这些化合物的合成方法。
• BETA-LACTAMASE INHIBITOR
  申请人：WUHAN VISION PHARMACEUTICAL TECHNOLOGY CO., LTD.

  公开号：US20190048027A1

  公开（公告）日：2019-02-14

  A beta-lactamase inhibitor having a formula (I). Also provided is a method of using the beta-lactamase inhibitor for prevention or treatment of diseases.

  一种具有化学式（I）的β-内酰胺酶抑制剂。还提供了一种使用该β-内酰胺酶抑制剂预防或治疗疾病的方法。
• One-Pot Generation of Lithium (Lithiophenyl)trialkoxyborates from Substituted Dihalobenzenes (Hal = Br, I) and Their Derivatization with Electrophiles
  作者：Paweł Kurach、Sergiusz Luliński、Janusz Serwatowski

  DOI：10.1002/ejoc.200800245

  日期：2008.6

  (halophenyl)trialkoxyborates were then subjected to halogen–lithium exchange in situ with a second equivalent of nBuLi to give dianionic lithium (lithiophenyl)trialkoxyborates. Treatment with selected electrophiles afforded substituted arylboronic acids and/or their pinacol esters as final products in moderate-to-good yields.(© Wiley-VCH Verlag GmbH & Co. KGaA, 69451 Weinheim, Germany, 2008)

  从 1,3- 和 1,4- 二碘苯以及几种活化的二溴苯和溴碘苯开始，已经开发出一种简单的一锅法合成有用的苯环上带有锂的苯基三烷氧基硼酸盐。转化的一般顺序包括使用 nBuLi 进行卤素-锂交换，然后用三烷基硼酸盐进行硼化。然后将所得（卤代苯基）三烷氧基硼酸锂与第二当量的 nBuLi 进行卤素-锂原位交换，得到双离子（硫代苯基）三烷氧基硼酸锂。用选定的亲电子试剂处理，以中等至良好的产率提供取代的芳基硼酸和/或其频哪醇酯作为最终产品。（© Wiley-VCH Verlag GmbH & Co. KGaA, 69451 Weinheim, Germany, 2008）
• Design, Synthesis, and Biological Activity of Novel 5-((Arylfuran/1<i>H</i>-pyrrol-2-yl)methylene)-2-thioxo-3-(3-(trifluoromethyl)phenyl)thiazolidin-4-ones as HIV-1 Fusion Inhibitors Targeting gp41
  作者：Shibo Jiang、Srinivasa R. Tala、Hong Lu、Nader E. Abo-Dya、Ilker Avan、Kapil Gyanda、Lu Lu、Alan R. Katritzky、Asim K. Debnath

  DOI：10.1021/jm101014v

  日期：2011.1.27

  5-((arylfuran/1H-pyrrol-2-yl)methylene)-2-thioxo-3-(3-(trifluoromethyl)phenyl)thiazolidin-4-ones (12a−o) as HIV-1 entry inhibitors. Compounds 12a−o effectively inhibited infection by both laboratory-adapted and primary HIV-1 strains and blocked HIV-1 mediated cell−cell fusion and gp41 six-helix bundle formation. Molecular docking analyses on two highly active inhibitors, 12b, containing a carboxylic

  在我们之前的分子对接分析的基础上，我们设计并合成了 5-((arylfuran/1 H -pyrrol-2-yl)methylene)-2-thioxo-3-(3-(trifluoromethyl)phenyl)thiazolidin-4- ( 12a - o ) 作为 HIV-1 进入抑制剂。化合物12a - o有效抑制实验室适应和原代 HIV-1 菌株的感染，并阻止 HIV-1 介导的细胞 - 细胞融合和 gp41 六螺旋束形成。两种高活性抑制剂12b和12m 的分子对接分析含有四唑基团，表明它们都紧贴在 HIV-1 gp41 的疏水腔中，每个都与赖氨酸 574 (K574) 具有重要的离子相互作用。相比之下，12i 的分子对接，一种含有吡咯而不是呋喃环的活性较低的化合物，表明与12b和12m 的取向完全不同，并且错过了关键的相互作用。